23
total announcements
ASTRAZEN.NS · 15 min delayed
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about General Updates, disclosing an ESG rating of 64 from Crisil ESG Ratings & Analytics Limited for fiscal year 2026.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about actions taken or orders passed regarding a demand notice issued by the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013. The Hon'ble High Court of Delhi has stayed the operation of the demand notice until the next date of hearing, subject to the Company depositing 15% of the amount mentioned in the demand notice.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about General Updates, specifically disclosing an ESG rating of 57 from Crisil ESG Ratings & Analytics Limited, based on publicly available information.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about a scheduled interaction with an institutional investor on August 26, 2026, via a virtual meeting.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about a scheduled interaction with analysts/investors on August 19, 2026, which may be subject to change.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on August 10, 2026, and informed the Exchange regarding voting results.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited reported a 30% growth in total revenue from operations to INR 6,828 Mn in Q1 FY2026–27, driven by continued momentum across its core therapy areas.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has held its 47th Annual General Meeting (AGM) on August 10, 2026, where it adopted financial statements, declared a dividend of Rs. 36 per equity share, and appointed new auditors and directors. The meeting was conducted through video conferencing, and remote e-voting was provided to members.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has submitted its financial results for the quarter ended June 30, 2026, reporting a 30% growth in total revenue from operations to INR 6,828 Mn in Q1 FY2026–27. The company's performance was driven by continued momentum across its core therapy areas—Oncology, Biopharmaceuticals (CVRM and R&I) and Rare Disease, reflecting the strength of its innovation-led strategy, disciplined execution and focus on improving patient outcomes in India.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization to import and sell Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu) for an additional indication in India.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013, amounting to Rs. 1,48,65,83,590, inclusive of interest calculated up to August 20, 2026. The company is evaluating the demand notice and appropriate legal actions.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013. The company is reviewing the notice and will take appropriate steps in accordance with applicable law.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization to import and distribute Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for an additional indication in India.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited informed the Exchange regarding 'Communication to the shareholders w.r.t. TDS on Dividend'. The company has sent an email communication to its shareholders regarding the deduction of tax at source on Dividend for the financial year 2025-26. The dividend will be paid after deducting tax at source under section 393 of the Income Tax Act, 2025. Resident shareholders with a total dividend amount to be paid in FY 27 not exceeding INR 10,000 will not have tax deducted at source. Tax will be deducted at 10% for resident shareholders not meeting the eligibility conditions, and 20% for non-resident shareholders.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about the dispatch of notice of the 47th Annual General Meeting (AGM) and e-voting information.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has announced a record date of July 31, 2026, for determining the entitlement of members eligible for the payment of a final dividend for the financial year 2025-26.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the financial year ended March 31, 2026'. The report includes details of the company's sustainability initiatives, governance, and financial performance.